Maze Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 4 days.
- Recent price momentum is -1.7% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 12.0% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | 34.4% | Better than 92% |
| Net margin | 2.0% | Better than 33% |
| Return on equity | -599.0% | Better than 1% |
| Return on invested capital | -305.0% | Better than 0% |
Momentum B-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 6.6% | Better than 86% |
| 6-month return | 21.7% | Better than 84% |
| 12-month return (ex latest month) | -14.5% | Better than 19% |
| Distance below 52-week high | 41.5% | Better than 27% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 15.5x | Better than 97% |
| Debt to assets | 5.9% | Better than 78% |
| Free cash flow / net income | 143.2% | Better than 63% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 96.9% | Better than 83% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 32.43
- Open
- 31.77
- Day range
- 30.88 - 32.80
- Avg price
- 31.67
- Volume
- 818.93K
- Turnover
- 25.94M
- Turnover ratei
- 2.20%
- Volume ratioi
- 0.93
- Amplitudei
- 5.92%
- 52-week rangei
- 21.95 - 53.65
Valuation
- P/Ei
- -11.80
- P/E (TTM)i
- -11.69
- P/Bi
- 4.00
- EPSi
- -2.66
- Book value / shi
- 7.84
- Net profit
- -145.35M
- Net assets
- 428.55M
Share structure
- Market cap
- 1.72B
- Float capi
- 1.17B
- Shares out
- 54.68M
- Float sharesi
- 37.25M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2025-01-31
41.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-3.86M net over the window
Short interest
- Shares short
- 6.68M
- % of floati
- 12.03%
- Days to coveri
- 8.76
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Maze Therapeutics (MAZE)?
Maze Therapeutics last traded at 31.37. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Maze Therapeutics's market cap?
About 1.72B.
What is the P/E ratio of Maze Therapeutics?
The trailing twelve-month P/E is -11.69, below its own 5-year average of 20.42 — in the middle of its historical range (43.61% percentile). See the Valuation tab for the full history.
Does Maze Therapeutics pay a dividend?
Maze Therapeutics does not currently pay a regular dividend.
Is Maze Therapeutics a buy according to analysts?
The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 61.78, which implies 96.9% upside from the current price. This is not investment advice.
What is Maze Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Maze Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Maze Therapeutics discussion 0 comments